Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04675710
Title Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

thyroid gland anaplastic carcinoma

Therapies

Dabrafenib + Pembrolizumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
M D Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field